Rasmussenbarbour6814

Recombinant protein production with Escherichia coli is usually carried out in fed-batch mode in industry. As set-up and cleaning of equipment are time- and cost-intensive, it would be economically and environmentally favorable to reduce the number of these procedures. Switching from fed-batch to continuous biomanufacturing with microbials is not yet applied as these cultivations still suffer from time-dependent variations in productivity. Repetitive fed-batch process technology facilitates critical equipment usage, reduces the environmental fingerprint and potentially increases the overall space-time yield. Surprisingly, studies on repetitive fed-batch processes for recombinant protein production can be found for yeasts only. Knowledge on repetitive fed-batch cultivation technology for recombinant protein production in E. coli is not available until now. In this study, a mixed feed approach, enabling repetitive fed-batch technology for recombinant protein production in E. coli, was developed. Effects of the cultivation mode on the space-time yield for a single-cycle fed-batch, a two-cycle repetitive fed-batch, a three-cycle repetitive fed batch and a chemostat cultivation were investigated. For that purpose, we used two different E. coli strains, expressing a model protein in the cytoplasm or in the periplasm, respectively. Our results demonstrate that a repetitive fed-batch for E. coli leads to a higher space-time yield compared to a single-cycle fed-batch and can potentially outperform continuous biomanufacturing. For the first time, we were able to show that repetitive fed-batch technology is highly suitable for recombinant protein production in E. coli using our mixed feeding approach, as it potentially (i) improves product throughput by using critical equipment to its full capacity and (ii) allows implementation of a more economic process by reducing cleaning and set-up times.Europe is often the center of origin of restrictions regarding technologies (e.g., biotechnologies GMOs and, more recently, gene editing). The causes have already been analyzed in relation to European regulations, but not to its deeply embedded roots. This is what the present article attempts to do. It first depicts the broader historical background in Europe, the rise of a new ideology aiming to avoid repetition of the tragedies of the past, and the way these postmodern ideas have been transposed to science, with a focus on the issue of technological risk. In contrast to Europe, the United States has not enacted biotechnology-inhibiting laws, and the reasons for such a difference are discussed.Bladder cancer is one of the most common cancers among men in industrialized countries and on the global level incidence and mortality rates are increasing. In spite of progress in surgical treatment and chemotherapy, the prognosis remains poor for patients with muscle-invasive bladder cancer. Therefore, there is a great need for the development of novel therapeutic approaches. The human amniotic membrane (hAM) is a multi-layered membrane that comprises the innermost part of the placenta. It has unique properties that make it suitable for clinical use, such as the ability to promote wound healing and decrease scarring, low immunogenicity, and immunomodulatory, antimicrobial and anticancer properties. This study aimed to investigate the effect of (i) hAM-derived cells and (ii) hAM scaffolds on the growth dynamics, proliferation rate, and invasive potential of muscle-invasive bladder cancer T24 cells. Our results show that 24 and 48 h of co-culturing T24 cells with hAM-derived cells (at 11 and 14 ratios) diminished the proliferation rate of T24 cells. Furthermore, when seeded on hAM scaffolds, namely (1) epithelium of hAM (e-hAM), (2) basal lamina of hAM (denuded; d-hAM), and (3) stroma of hAM (s-hAM), the growth dynamic of T24 cells was altered and proliferation was reduced, even more so by the e-hAM scaffolds. Importantly, despite their muscle-invasive potential, the T24 cells did not disrupt the basal lamina of hAM scaffolds. Furthermore, we observed a decrease in the expression of epithelial-mesenchymal transition (EMT) markers N-cadherin, Snail and Slug in T24 cells grown on hAM scaffolds and individual T24 cells even expressed epithelial markers E-cadherin and occludin. Our study brings new knowledge on basic mechanisms of hAM affecting bladder carcinogenesis and the results serve as a good foundation for further research into the potential of hAM-derived cells and the hAM extracellular matrix to serve as a novel bladder cancer treatment.A new photocatalyst denoted as mTHPC/pCN was prepared by modifying protonated graphitic carbon nitride (pCN) by meso-tetrahydroxyphenylchlorin (mTHPC). Relevant samples were characterized via various methods including zeta potential measurements, X-ray diffraction, Fourier transform infrared spectroscopy, X-ray photoelectron spectroscopy, N2 adsorption-desorption, transmission electron microscopy, ultraviolet-visible-near-infrared spectroscopy, electrochemical impedance spectroscopy, photocurrent response measurements, electron spin resonance spectroscopy, and phosphorescence spectroscopy. Compared with pCN, mTHPC/pCN shows enhanced absorption in the visible and near-infrared regions and thus higher photocatalytic activity in hydrogen evolution. A possible mechanism for mTHPC/pCN is proposed.The development of new strategies to turn achiral artificial hosts into highly desirable chiral receptors is a crucial challenge in order to advance the fields of asymmetric transformations and enantioselective sensing. Over the past few years, C3 symmetrical cages have emerged as interesting class of supramolecular hosts that have been reported as efficient scaffolds for chirality dynamics (such as generation, control, and transfer). On this basis, this mini review, which summarizes the existing examples of chirality control and propagation in tripodal supramolecular cages, aims at discussing the benefits and perspectives of this approach.Nanotechnology has made a significant impact on basic and clinical cancer research over the past two decades. RMC-6236 supplier Owing to multidisciplinary advances, cancer nanotechnology aims to address the problems in current cancer treatment paradigms, with the ultimate goal to improve treatment efficacy, increase patient survival, and decrease toxic side-effects. The potential for use of nanomedicine in cancer targeting and therapy has grown, and is now used to advance the four traditional pillars of cancer treatment surgery, chemotherapy, radiation therapy and the newest pillar, immunotherapy. In this review we provide an overview of notable advances of nanomedicine in improving drug delivery, radiation therapy and immunotherapy. Potential barriers in the translation of nanomedicine from bench to bedside as well as strategies to overcome these barriers are also discussed. Promising preclinical findings highlight the translational and clinical potential of integrating nanotechnology approaches into cancer care.